Log in to search using one of your social media accounts:

 

Is Peritoneal Cancer Hereditary?
Title: Is Peritoneal Cancer Hereditary?Category: Doctor's& Expert's views on SymptomsCreated: 10/13/2017 12:00:00 AMLast Editorial Review: 10/13/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 13, 2017 Category: Cancer & Oncology Source Type: news

Ovarian Fallopian Tube Primary Peritoneal Cancer
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

ovarian epithelial fallopian cancer
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 27, 2017 Category: General Medicine Source Type: news

HIPEC for Colorectal Cancer With Peritoneal Carcinomatosis
This video reviews the use of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer with peritoneal carcinomatosis. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Hans Schlitt, MD Tags: Videos Gastrointestinal Cancers Source Type: news

Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis Case: Coccidioidomycosis Mimicking Peritoneal Carcinomatosis
New onset ascites, lymphadenopathy, and peritoneal nodules suggested a metastatic carcinomatosis in this patient; but her residence in Arizona provided the key to the correct diagnosis.Applied Radiology (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - May 8, 2017 Category: Radiology Tags: Radiology Journal Article Source Type: news

New Approaches Needed for Peritoneal Metastases in CRC New Approaches Needed for Peritoneal Metastases in CRC
Dr David Kerr challenges the oncology community to come up with rational, meaningful clinical trials to clarify the biology of metastatic peritoneal disease in colorectal cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 13, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

FDA Approves Niraparib for Recurrent Ovarian Cancer
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Source Type: news

FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 27, 2017 Category: American Health Source Type: news

Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news

Low Recurrence After Risk-Reducing Surgery for BRCA Carriers Low Recurrence After Risk-Reducing Surgery for BRCA Carriers
Dr Maurie Markman discusses the results of an RRSO surgery study showing a 1% incidence rate in long-term follow-up of subsequent peritoneal cancer.Medscape Oncology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 24, 2017 Category: Surgery Tags: Hematology-Oncology Commentary Source Type: news

Bevacizumab Approved for Another Type of Ovarian Cancer Bevacizumab Approved for Another Type of Ovarian Cancer
The latest FDA approval is for use in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: World Pharma News)
Source: World Pharma News - December 9, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - December 7, 2016 Category: Pharmaceuticals Source Type: news

Roche ’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab), either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. (Source: Roche Media News)
Source: Roche Media News - December 7, 2016 Category: Pharmaceuticals Source Type: news

Poorer Prognosis for Peritoneal Metastatic Colorectal Cancer Poorer Prognosis for Peritoneal Metastatic Colorectal Cancer
Colorectal cancer patients with peritoneal metastases have a worse prognosis than those with metastatic tumors in other locations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The Surgical Management of Peritoneal Carcinomatosis of Colorectal Origin
In the United States, approximately 20% of patients with colorectal cancer present with distant metastasis at diagnosis. In 25% of cases, the peritoneal cavity is the only site of metastatic disease, which is not indicative of a generalized systemic disease, as is the case with lung or liver metastases. (Source: CancerNetwork)
Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Daniel M. Labow, MD Ramy Fouad, MD Shanel B. Bhagwandin, DO, MPH Tags: Colorectal Cancer Oncology Journal Source Type: news

HIPEC and Surgery for Peritoneal CarcinomatosisHIPEC and Surgery for Peritoneal Carcinomatosis
How effective is hyperthermic intraperitoneal chemotherapy? Which patients benefit the most? Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Research uncovers more inherited genetic mutations linked to ovarian cancer
(Care New England ) Previous research has established a link between genetic mutations in the BRCA1 and BRCA2 genes to an increased risk of developing ovarian, fallopian tube or peritoneal cancer in women. A recent publication documents the efforts of a team of researchers affiliated with the Gynecologic Oncology Group (GOG) to determine if inherited genetic mutations other than BRCA1 and BRCA2 can also put a woman at risk of developing these diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 10, 2016 Category: Cancer & Oncology Source Type: news

10 Must-Do Health Checks For Women Over 50
This article first appeared on the Golden Girls Network blog. Earlier on Huff/Post50: -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - October 31, 2015 Category: Consumer Health News Source Type: news

Genetic testing all women for breast cancer might not be worth the cost
Women who are carriers of mutated BRCA genes are known to have a significantly higher risk for developing breast and ovarian cancers than those who don’t. But a new study by UCLA faculty questions the value of screening for the genetic mutations in the general population — including those who do not have cancer or have no family history of the disease — because of the high cost. The UCLA researchers found that compared with universal screening, other diagnostic tools remain more efficient and might be more cost-effective.  The paper was authored by Dr. Patricia Ganz, director of the division of cance...
Source: UCLA Newsroom: Health Sciences - September 4, 2015 Category: Universities & Medical Training Source Type: news

Acetic Acid in Vinegar Kills Mesothelioma Cells
For more than 2,000 years, people have used vinegar to preserve and flavor food, disinfect wounds and treat a wide range of ailments, from stomach aches to diabetes. Yet modern scientists remain skeptical of these storied medicinal benefits, often dismissing vinegar-based treatments as folk remedies with questionable proof behind them. However, a recent study published in the December 2014 issue of Journal of Gastroenterology and Hepatology suggests this perception soon may change — especially when it comes to mesothelioma treatment. "Acetic acid is a powerful anticancer agent," wrote Susumu Okabe, lead aut...
Source: Asbestos and Mesothelioma News - January 21, 2015 Category: Environmental Health Authors: Joey Rosenberg Tags: Treatment & Doctors Source Type: news

Researchers Evaluating Proposed Peritoneal Mesothelioma Staging System
Data gathered by an international group of peritoneal mesothelioma experts is leading to changes in the way patients with this rare asbestos-related disease are diagnosed and treated. The cancer's rarity and resistance to treatment have complicated past efforts to create a formal staging system. Its low incidence also has limited the amount of data necessary to ensure a staging system is useful. Dr. W. Charles Conway, of the Ochsner Cancer Institute in New Orleans, offers insight into a batch of data collected over a 20-year span that is paving the path toward formalizing a staging system for this rare cancer. "The...
Source: Asbestos and Mesothelioma News - September 12, 2014 Category: Environmental Health Authors: Michelle Whitmer Tags: Research & Clinical Trials Source Type: news

Hyperthermic Peritoneal Chemo in Peritoneal Carcinoma...Hyperthermic Peritoneal Chemo in Peritoneal Carcinoma...
Hyperthermic intraperitoneal chemotherapy (HIPEC) can be administered with acceptable morbidity and mortality for selected patients with peritoneal carcinomatosis, according to a new report. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Task Force recommends BRCA mutation screening for high-risk women
According to a new guideline being published in Annals of Internal Medicine, the United States Preventive Services Task Force (USPSTF) recommends that primary care providers screen asymptomatic women with a family history of breast, ovarian, tubal, or peritoneal cancers to determine if that family history may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes BRCA1 or BRCA2. Women who screen positive should have genetic counseling and, if indicated after counseling, BRCA testing. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 23, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

NICE issues ACD on bevacizumab for recurrent advanced platinum sensitive or partially platinum sensitive ovarian, fallopian tube, and primary peritoneal cancer
Source: NICE Area: News The National Institute for Health and Clinical Excellence (NICE) has issued for consultation an Appraisal Consultation Document (ACD) on the use of bevacizumab for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease).   The following preliminary recommendations have been made:   . Bevacizumab in combination with gemcitabine and carboplatin is not recommended for treating the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary ...
Source: NeLM - News - February 1, 2013 Category: Drugs & Pharmacology Source Type: news